Serum-starved ERBB2-positive SKBr3 breast cancer cells were exposed to EGF or heregulin (HRG) to activate HER2 through EGFR/HER2 and HER2/HER3 signalling routes, respectively. Here, ERBB2 is linked to breast carcinoma.